BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kadoya T, Sakakibara A, Kitayama K, Yamada Y, Higuchi S, Kawakita R, Kawasaki Y, Fujino M, Murakami Y, Shimura M, Murayama K, Ohtake A, Okazaki Y, Koga Y, Yorifuji T. Successful treatment of infantile-onset ACAD9-related cardiomyopathy with a combination of sodium pyruvate, beta-blocker, and coenzyme Q10. Journal of Pediatric Endocrinology and Metabolism 2019;32:1181-5. [DOI: 10.1515/jpem-2019-0205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Koňaříková E, Marković A, Korandová Z, Houštěk J, Mráček T. Current progress in the therapeutic options for mitochondrial disorders. Physiol Res 2020;69:967-94. [PMID: 33129249 DOI: 10.33549/physiolres.934529] [Reference Citation Analysis]
2 Banshoya K, Nakamura T, Tanaka T, Kaneo Y. Coenzyme Q10-Polyethylene Glycol Monostearate Nanoparticles: An Injectable Water-Soluble Formulation. Antioxidants (Basel) 2020;9:E86. [PMID: 31963934 DOI: 10.3390/antiox9010086] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
3 Gueguen N, Piarroux J, Sarzi E, Benkirane M, Manes G, Delettre C, Amedro P, Leboucq N, Koenig M, Meyer P, Meunier I, Reynier P, Lenaers G, Roubertie A. Optic neuropathy linked to ACAD9 pathogenic variants: A potentially riboflavin-responsive disorder? Mitochondrion 2021;59:169-74. [PMID: 34023438 DOI: 10.1016/j.mito.2021.05.002] [Reference Citation Analysis]